Text Size

The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients

This study has been completed.
Sponsor:
Collaborator:
Fresenius AG
Information provided by:
University Medicine Greifswald
ClinicalTrials.gov Identifier:
NCT00142220
First received: August 31, 2005
Last updated: September 8, 2006
Last verified: September 2006
History of Changes
  Purpose

We study whether an increased proportion of omega-3-fatty acids (contained in fish oil) in the nutrition of critically ill patients reduces systemic inflammation.


Condition Intervention Phase
Sepsis Syndrome
 Drug: Defined percentage of omega-3-fatty acids
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Comparison Between Two Different Proportions of Omega-3- and Omega-6-Fatty Acids in the Parenteral Nutrition of Critically Ill Patients

Resource links provided by NLM:

MedlinePlus related topics: Sepsis
U.S. FDA Resources

Further study details as provided by University Medicine Greifswald:

Primary Outcome Measures:
  • level of IL-6 in serum
  • HLA-expression on monocytes

Secondary Outcome Measures:
  • number of nosocomial infections
  • days on mechanical ventilation
  • duration of ICU stay
  • mortality
  • SOFA score

Estimated Enrollment: 160
Study Start Date: January 2004
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • indication for parenteral nutrition

Exclusion Criteria:

  • hypertriglyceridemia
  • coagulation disorder
  • decompensated liver cirrhosis or acute liver failure
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00142220

Locations
Germany
Internistische ITS
Greifswald, Germany, 17475
Sponsors and Collaborators
University Medicine Greifswald
Fresenius AG
Investigators
Principal Investigator: Sigrun Friesecke, Dr. University Medicine Greifswald
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00142220     History of Changes
Other Study ID Numbers: OMEGAVEN
Study First Received: August 31, 2005
Last Updated: September 8, 2006
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Critical Illness
Sepsis
Systemic Inflammatory Response Syndrome
Disease Attributes
 Pathologic Processes
Infection
Inflammation
Shock

ClinicalTrials.gov processed this record on May 16, 2013